## Agenda for Quarterly Meeting on MDUFA II (2008-2012) Performance February 12, 2012 10:00 A.M.

Welcome. Barbara Zimmerman, CDRH-ODE.

### FDA MDUFMA / MDUFA Performance — Actions through Sept 30, 2012

- Reports on all decision goals for the FY 2008 FY 2012 cohorts.
  - o CBER: Sheryl Kochman, CBER.
  - o CDRH: Barbara Zimmerman, CDRH.

### **CLIA Waiver Review Times**

• Report on qualitative goals and number of pending waiver requests, CDRH-OIR.

### **Qualitative Update on Finances – 4th Quarter of FY 2012**

• User fee receipts through the 4th quarter of FY 2012. Lisa Berry, FDA-OFM.

### Quarterly Update on Medical Device Performance Goals

— CBER Performance Data —


Actions through 31 December 2012

### Data on FY 2008 - FY 2012 Cohorts

Actions through 31 December 2012


### **PMAs and Panel-track Supplements**

	FY 2008	FY 2009	FY 2010	FY 2011	FY 2012
Workload (Filed to Date)	0	2	0	1	4
Total FDA Decisions	0	2	0	1	2
Percent within Tier 1 goal (180 days)		100.0%		100.0%	50.0%
Tier 1 goal — Percent within 180 days	60%	60%	60%	60%	60%
Percent within Tier 2 goal (295 days)		100.0%		100.0%	50.0%
Tier 2 goal — Percent within 295 days	90%	90%	90%	90%	90%
Cohort status	Complete	Complete	Complete	Complete	Open




### **Expedited PMAs and Expedited Panel-track Supplements**

	FY 2008	FY 2009	FY 2010	FY 2011	FY 2012
Workload (Filed to Date)	0	0	1	0	0
Total FDA Decisions	0	0	1	0	0
Percent within Tier 1 goal (180 days)			100.0%		
Tier 1 goal — Percent within 180 days	50%	50%	50%	50%	50%
Percent within Tier 2 goal (280 days)			100.0%		
Tier 2 goal — Percent within 280 days	90%	90%	90%	90%	90%
Cohort status	Complete	Complete	Complete	Complete	Complete




#### **PMA Modules**

	FY 2008	FY 2009	FY 2010	FY 2011	FY 2012
Workload (Filed to Date)	0	0	1	5	4
MDUFMA Cohort	0	0	1	5	4
Total FDA Decisions	0	0	1	5	3
Percent within Tier 1 goal (90 days)			100.0%	100.0%	100.0%
Tier 1 goal — Percent within 90 days	75%	75%	75%	75%	75%
Percent within Tier 2 goal (120 days)			100.0%	100.0%	100.0%
Tier 2 goal — Percent within 120 days	90%	90%	90%	90%	90%
Cohort status	Complete	Complete	Complete	Complete	Open




### 180-day PMA Supplements

	FY 2008	FY 2009	FY 2010	FY 2011	FY 2012
Workload (Filed to Date)	5	7	7	9	7
Total FDA Decisions	5	7	7	9	6
Percent within Tier 1 goal (180 days)	80.0%	85.7%	100.0%	100.0%	83.3%
Tier 1 goal — Percent within 180 days	85%	85%	85%	85%	85%
Percent within Tier 2 goal (210 days)	80.0%	100.0%	100.0%	100.0%	100.0%
Tier 2 goal — Percent within 210 days	95%	95%	95%	95%	95%
Cohort status	Complete	Complete	Complete	Complete	Open




### **Real-time PMA Supplements**

	FY 2008	FY 2009	FY 2010	FY 2011	FY 2012
Workload (Filed to Date)	2	4	2	1	4
Total FDA Decisions	2	4	2	1	4
Percent within Tier 1 goal (60 days)	100.0%	100.0%	100.0%	100.0%	100.0%
Tier 1 goal — Percent within 60 days	80%	80%	80%	80%	80%
Percent within Tier 2 goal (90 days)	100.0%	100.0%	100.0%	100.0%	100.0%
Tier 2 goal — Percent within 90 days	90%	90%	90%	90%	90%
Cohort status	Complete	Complete	Complete	Complete	Complete



### 510(k)s

	FY 2008	FY 2009	FY 2010	FY 2011	FY 2012
Workload (Received to Date)	53	50	55	44	54
MDUFMA Cohort	49	40	43	34	49
Total FDA Decisions	49	40	43	32	40
Percent within Tier 1 goal (90 days)	95.9%	95.0%	97.7%	96.9%	100.0%
Tier 1 goal — Percent within 90 days	90%	90%	90%	90%	90%
Percent within Tier 2 goal (150 days)	98.0%	100.0%	100.0%	100.0%	100.0%
Tier 2 goal — Percent within 150 days	98%	98%	98%	98%	98%
Cohort status	Complete	Complete	Complete	Open	Open




# Quarterly Update on Medical Device Performance Goals ---- CDRH Performance Data ----

Action through 31 December 2012


### MDUFA II Quarterly (Non expedited PMA Orginal and Panel-track Supplements) For Submissions Filed Between Year 2008 to 2012 as of 12/31/2012 11:59:00 PM

	FY 2008	FY 2009	FY 2010	FY 2011	FY 2012
Workload (Filed to Date)	33	39	53	44	30
Total FDA Decision	33	39	53	41	16
Tier 1 goal Percent within 180 Days	60%	60%	60%	60%	60%
Goal met(yes/no/unknown)	yes	yes	yes	yes	unknown
Pending Performance-Best Case	64%	77%	79%	82%	100%
Pending Performance-Worst Case	64%	77%	79%	75%	53%
Tier 2 goal Percent within 295 days	90%	90%	90%	90%	90%
Goal met(yes/no/unknown)	no	no	yes	yes	unknown
Pending Performance-Best Case	79%	85%	96%	98%	100%
Pending Performance-Worst Case	79%	85%	96%	91%	53%
Cohort status	Complete	Complete	Complete	Open	Open




### MDUFA II Quarterly (Expedited PMA Orginal and Expedited Panel-Track Supplements)

	FY 2008	FY 2009	FY 2010	FY 2011	FY 2012
Workload (Filed to Date)	4	4	6	7	3
Total FDA Decision	4	4	5	6	3
Tier 1 goal Percent within 180 Days	50%	50%	50%	50%	50%
Goal met(yes/no/unknown)	no	yes	no	no	yes
Pending Performance-Best Case	25%	50%	33%	14%	67%
Pending Performance-Worst Case	25%	50%	33%	14%	67%
Tier 2 goal Percent within 280 days	90%	90%	90%	90%	90%
Goal met(yes/no/unknown)	no	no	no	no	yes
Pending Performance-Best Case	50%	75%	83%	57%	100%
Pending Performance-Worst Case	50%	75%	83%	57%	100%
Cohort status	Complete	Complete	Open	Open	Complete




### **MDUFA II Quarterly (Modular PMA)**

	FY 2008	FY 2009	FY 2010	FY 2011	FY 2012
Workload (Cycle Started)	57	90	104	85	64
Total FDA Decision	57	90	103	85	62
Tier 1 goal Percent within 90 Days	75%	75%	75%	75%	75%
Goal met(yes/no/unknown)	no	no	yes	yes	no
Pending Performance-Best Case	54%	69%	78%	86%	73%
Pending Performance-Worst Case	54%	69%	78%	86%	70%
Tier 2 goal Percent within 120 days	90%	90%	90%	90%	90%
Goal met(yes/no/unknown)	no	yes	yes	yes	unknown
Pending Performance-Best Case	88%	92%	97%	95%	91%
Pending Performance-Worst Case	88%	92%	97%	95%	88%
Cohort status	Complete	Complete	Complete	Complete	Open




### **MDUFA II Quarterly (180-day PMA Supplements)**

	FY 2008	FY 2009	FY 2010	FY 2011	FY 2012
Moulded (Filed to Date)					
Workload (Filed to Date)	170	165	157	145	210
Total FDA Decision	160	158	132	129	96
Tier 1 goal Percent within 180 Days	85%	85%	85%	85%	85%
Goal met(yes/no/unknown)	yes	yes	yes	yes	unknown
Pending Performance-Best Case	90%	85%	86%	95%	99%
Pending Performance-Worst Case	90%	85%	86%	95%	49%
Tier 2 goal Percent within 210 days	95%	95%	95%	95%	95%
Goal met(yes/no/unknown)	yes	no	yes	yes	unknown
Pending Performance-Best Case	96%	92%	95%	100%	99%
Pending Performance-Worst Case	96%	92%	95%	100%	49%
Cohort status	Complete	Complete	Complete	Complete	Open




### **MDUFA II Quarterly (Real Time PMA Supplements)**

	FY 2008	FY 2009	FY 2010	FY 2011	FY 2012
Workload (Filed to Date)	249	296	269	245	305
Total FDA Decision	241	281	257	235	293
Tier 1 goal Percent within 60 Days	80%	80%	80%	80%	80%
Goal met(yes/no/unknown)	yes	yes	yes	yes	yes
Pending Performance-Best Case	92%	93%	92%	95%	95%
Pending Performance-Worst Case	92%	93%	92%	95%	95%
Tier 2 goal Percent within 90 days	90%	90%	90%	90%	90%
Goal met(yes/no/unknown)	yes	yes	yes	yes	yes
Pending Performance-Best Case	97%	97%	100%	98%	98%
Pending Performance-Worst Case	97%	97%	100%	98%	98%
Cohort status	Complete	Complete	Complete	Complete	Open



### **MDUFA II Quarterly (510(k) Premarket Notifications)**

					1
	FY 2008	FY 2009	FY 2010	FY 2011	FY 2012
Workload (Received to Date)	3,848	4,103	3,880	3,833	3,994
MDUFA Cohort	3,260	3,402	3,147	3,206	3,650
Total FDA Decision	3,259	3,398	3,141	3,185	2,702
Tier 1 goal Percent within 90 Days	90%	90%	90%	90%	90%
Goal met(yes/no/unknown)	yes	yes	yes	yes	unknown
Pending Performance-Best Case	94%	90%	91%	95%	98%
Pending Performance-Worst Case	94%	90%	90%	95%	72%
Tier 2 goal Percent within 150 Days	98%	98%	98%	98%	98%
Goal met(yes/no/unknown)	yes	yes	yes	yes	unknown
Pending Performance-Best Case	98%	98%	98%	99%	100%
Pending Performance-Worst Case	98%	98%	98%	99%	74%
Cohort status	Open	Open	Open	Open	Open



### **CLIA** Waiver by Application

MDUFA II Cohort Summary as of 1/18/2013							
	FY08	FY09	FY10	FY11	FY12		
Received	12	7	5	6	6		
Approved	5	3	2	3	2		
Denied	6	3	3	0	4		
No Response		0	0	1	0		
Necessary	0	J	J	I	U		
On Hold	1	1	0	2	0		

Fiscal Year         Recommendation         Total FDA Days         Total Mfr Days         Total days           2008         Approved         398         0         398           61         0         61         0         61           248         38         286         248         38         286           248         398         0         398         0         398           Denied         287         0         287         199         0         199           189         0         189         320         424         744         129         0         129           102         0         102         0         102	
2008         Approved         398         0         398           61         0         61         248         38         286           248         38         286         248         38         286           398         0         398         0         398           Denied         287         0         287           199         0         199           189         0         189           320         424         744           129         0         129           102         0         102           Telephone Hold         136         1691         1827           2009         Approved         233         0         233	
61	
248     38     286       398     0     398       Denied     287     0     287       199     0     199       189     0     189       320     424     744       129     0     129       102     0     102       Telephone Hold     136     1691     1827       2009     Approved     233     0     233	
Denied     248     38     286       398     0     398       Denied     287     0     287       199     0     199       189     0     189       320     424     744       129     0     129       102     0     102       Telephone Hold     136     1691     1827       2009     Approved     233     0     233	
Denied 287 0 287  199 0 199  189 0 189  320 424 744  129 0 129  102 0 102  Telephone Hold 136 1691 1827  2009 Approved 233 0 233	
Denied     287     0     287       199     0     199       189     0     189       320     424     744       129     0     129       102     0     102       Telephone Hold     136     1691     1827       2009     Approved     233     0     233	
189 0 189   320 424 744   129 0 129   102 0 102   Telephone Hold 136 1691 1827   2009 Approved 233 0 233	
189 0 189   320 424 744   129 0 129   102 0 102   Telephone Hold 136 1691 1827   2009 Approved 233 0 233	
320   424   744   129   0   129     102   0   102     102     102     102   1691   1827   1691   1827   1691   1827   1691   1	
Telephone Hold         102         0         102           2009         Approved         233         0         233	
Telephone Hold         102         0         102           2009         Approved         233         0         233	
Telephone Hold         136         1691         1827           2009         Approved         233         0         233	
2009 Approved 233 0 233	
304 908 1212	
Denied 740 0 740	
285 0 285	
644 7 651	
Telephone Hold 33 1416 1449	
2010 Approved 77 0 77	
105 106 211	
Denied 172 0 172	
266 0 266	
248 0 248	
2011 Approved 27 0 27	
229 97 326	
165 87 252	
No Response	
Necessary         715         0         715	
Request For	
Additional	
Information 95 392 487	
95 392 487	
2012 Approved 79 0 79	
24 0 24	
Denied 153 0 153	
64 56 120	
235 0 235	
165 0 165	

FY 2012 Medical Device User Fee Collections
as of September 30, 2012 $^{\prime 1}$
Excludes Unearned Fees

	Receipts	Refunds	Net	Authorized	% of Authorized	FY 2012 Surplus
Registration Fees	\$33,392,403	\$353,217	\$33,039,186			
Application Fees	\$29,835,391	\$274,714	\$29,560,677			
Total	\$63,227,794	\$627,931	\$62,599,863	\$57,605,000	109.8%	\$4,994,863

Medical Device User Fee Collection History 1/2 Excludes Unearned Fees, Includes Refunds								
FY 2003	FY 2004	FY 2005	FY 2006	FY 2007	FY 2008	FY 2009	FY 2010	FY 2011
\$21,620,549	\$26,280,073	\$31,680,296	\$34,470,161	\$27,808,956	\$47,621,685	\$55,816,125	\$62,794,058	\$69,550,011

### Notes:

 $<sup>^{\</sup>prime 1}$  Collections in this section are attributed to the authorized revenue ceiling for Cohort Year 2012.

<sup>&</sup>lt;sup>/2</sup> Collections in this section are attributed to the authorized revenue ceiling of the Cohort Year listed.